Gene info: ID 8529

Gene: CYP4F2

GENE ID: 8529

Synonyms: CPF2

Description: cytochrome P450 family 4 subfamily F member 2

Gene type: protein-coding

Location: 19p13.12

dbXrefs: Ensembl:ENSG00000186115 MIM:604426 Vega:OTTHUMG00000185995 UniprotKB:P78329

RefSeq: NG_007971.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND|AD

# Publications: 10

Sherlock p-value : 9.127e-1 (AD) 4.011e-1 (ND) (Frontal_Cortex)

Pascal p-value : 7.519e-1 (AD) 9.507e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
CES3	0.54
LPA	0.521
GOLGA8B	0.51
RANBP17	0.501
LRMP	0.501
MPO	0.5
AGBL3	0.497
FAM228A	0.497
TARBP1	0.492
NLRP3	0.485

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
CCDC102A	-0.354
HVCN1	-0.283
AKR1C3	-0.277
DLEU1	-0.275
MDFI	-0.27
C7orf61	-0.264
WDR38	-0.262
RLN2	-0.255
LHFPL1	-0.252
LYPD1	-0.244

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB08868	Fingolimod	Small Molecule	162359-55-9	Approved\|Investigational	Enzyme
DB09148	Florbetaben (18F)	Small Molecule	902143-01-5	Approved	Enzyme

ID	Drug Name	Action	PubMed
C006551	2-amino-2-methyl-1-propanol	2-amino-2-methyl-1-propanol results in decreased expression of CYP4F2 mRNA	25088246
C457499	2-chloro-5-nitrobenzanilide	2-chloro-5-nitrobenzanilide promotes the reaction [Ethanol results in decreased expression of CYP4F2 protein]	28062356
C457499	2-chloro-5-nitrobenzanilide	2-chloro-5-nitrobenzanilide results in decreased expression of CYP4F2 protein	28062356
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA]"	21205922
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [Genistein results in increased expression of CYP4F2 mRNA]"	21205922
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in increased expression of CYP4F2 mRNA]"	21205922
C000595015	6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	"6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine results in increased expression of CYP4F2 mRNA"	28073004
C512408	A 769662	A 769662 results in increased expression of CYP4F2 mRNA	21205922
D000074	Acenocoumarol	CYP4F2 gene polymorphism affects the susceptibility to Acenocoumarol	19578179
D000074	Acenocoumarol	CYP4F2 polymorphism affects the susceptibility to Acenocoumarol	25042728
D000082	Acetaminophen	Acetaminophen results in decreased expression of CYP4F2 mRNA	26690555
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of CYP4F2 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of CYP4F2 mRNA	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of CYP4F2 mRNA	21641981
C031143	AICA ribonucleotide	"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA]"	21205922
C031143	AICA ribonucleotide	AICA ribonucleotide results in increased expression of CYP4F2 mRNA	21205922
C031143	AICA ribonucleotide	PRKAA1 protein affects the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA]	21205922
C031143	AICA ribonucleotide	PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA]	21205922
D024502	alpha-Tocopherol	alpha-Tocopherol inhibits the reaction [Ethanol results in decreased expression of CYP4F2 protein]	28062356
D024502	alpha-Tocopherol	alpha-Tocopherol results in increased expression of CYP4F2 mRNA	28062356
D024502	alpha-Tocopherol	alpha-Tocopherol results in increased expression of CYP4F2 protein	28062356
D000535	Aluminum	[APP protein modified form binds to Aluminum] which results in decreased expression of CYP4F2 mRNA	21298039
D000638	Amiodarone	Amiodarone affects the expression of CYP4F2 mRNA	18355885
D000639	Amitriptyline	Amitriptyline affects the expression of CYP4F2 mRNA	18355885
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of CYP4F2 mRNA	20106945
D004958	Estradiol	Estradiol results in decreased expression of CYP4F2 mRNA	20106945
C006780	bisphenol A	bisphenol A results in decreased expression of CYP4F2 mRNA	25181051
D002995	Clofibric Acid	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of CYP4F2 mRNA	17602206
D002997	Clomipramine	Clomipramine affects the expression of CYP4F2 mRNA	18355885
D003300	Copper	Copper results in decreased expression of CYP4F2 mRNA	22465980
D016572	Cyclosporine	Cyclosporine results in decreased expression of CYP4F2 mRNA	20106945\|2556210
D003671	DEET	[fipronil co-treated with DEET] results in decreased expression of CYP4F2 mRNA	27091632
D003703	Demecolcine	Demecolcine results in increased expression of CYP4F2 mRNA	23649840
D003976	Diazinon	Diazinon results in decreased methylation of CYP4F2 gene	22964155
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in increased expression of CYP4F2 mRNA	27392435
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of CYP4F2 mRNA	17602206
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4F2 mRNA	18544905
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of CYP4F2 mRNA	19638242
D000431	Ethanol	2-chloro-5-nitrobenzanilide promotes the reaction [Ethanol results in decreased expression of CYP4F2 protein]	28062356
D000431	Ethanol	alpha-Tocopherol inhibits the reaction [Ethanol results in decreased expression of CYP4F2 protein]	28062356
D000431	Ethanol	Ethanol results in decreased expression of CYP4F2 mRNA	28062356
D000431	Ethanol	Ethanol results in decreased expression of CYP4F2 protein	28062356
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of CYP4F2 mRNA	23649840
D011345	Fenofibrate	Fenofibrate results in decreased expression of CYP4F2 protein	15964316
C082360	fipronil	[fipronil co-treated with DEET] results in decreased expression of CYP4F2 mRNA	27091632
D005557	Formaldehyde	Formaldehyde results in increased expression of CYP4F2 mRNA	23649840
D019833	Genistein	"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [Genistein results in increased expression of CYP4F2 mRNA]"	21205922
D019833	Genistein	Genistein results in increased expression of CYP4F2 mRNA	21205922
D019833	Genistein	STO 609 inhibits the reaction [Genistein results in increased expression of CYP4F2 mRNA]	21205922
D007099	Imipramine	Imipramine affects the expression of CYP4F2 mRNA	18355885
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in increased expression of CYP4F2 mRNA	27392435
D007654	Ketoconazole	Ketoconazole results in decreased activity of CYP4F2 protein	14709627
D007654	Ketoconazole	Ketoconazole affects the expression of CYP4F2 mRNA	18355885
C011890	kojic acid	[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4F2 mRNA	18544905
C030814	menatetrenone	CYP4F2 gene SNP affects the abundance of menatetrenone	25747538
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of CYP4F2 mRNA	23649840
C503100	N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide	N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide results in decreased activity of CYP4F2 protein	15831442
C046012	pentanal	pentanal results in increased expression of CYP4F2 mRNA	26079696
C027579	periodate-oxidized adenosine	periodate-oxidized adenosine affects the expression of CYP4F2 mRNA	17097637
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CYP4F2 mRNA	19710929
C006253	pirinixic acid	pirinixic acid results in decreased expression of CYP4F2 protein	15964316
C005556	propionaldehyde	propionaldehyde results in increased expression of CYP4F2 mRNA	26079696
C059514	resveratrol	"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [resveratrol results in increased expression of CYP4F2 mRNA]"	21205922
C059514	resveratrol	resveratrol results in increased expression of CYP4F2 mRNA	21205922
C059514	resveratrol	splitomicin inhibits the reaction [resveratrol results in increased expression of CYP4F2 mRNA]	21205922
D015474	Isotretinoin	Isotretinoin results in decreased expression of CYP4F2 mRNA	20436886
C089730	rosiglitazone	rosiglitazone results in decreased expression of CYP4F2 mRNA	25572481
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of CYP4F2 mRNA	25895662
D012999	Soman	Soman results in decreased expression of CYP4F2 mRNA	19281266
C444426	splitomicin	splitomicin inhibits the reaction [resveratrol results in increased expression of CYP4F2 mRNA]	21205922
C458525	STO 609	STO 609 inhibits the reaction [Genistein results in increased expression of CYP4F2 mRNA]	21205922
C016766	sulforafan	sulforafan results in increased expression of CYP4F2 mRNA	26833863
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of CYP4F2 mRNA	21998131
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of CYP4F2 mRNA"	26179874
C057693	troglitazone	troglitazone results in decreased expression of CYP4F2 mRNA	25572481
D014520	Urethane	Urethane results in decreased expression of CYP4F2 mRNA	28818685
D014750	Vincristine	Vincristine results in increased expression of CYP4F2 mRNA	23649840
D014812	Vitamin K	CYP4F2 protein affects the metabolism of Vitamin K	19741565
D010837	Vitamin K 1	CYP4F2 gene polymorphism results in decreased metabolism of Vitamin K 1	22417713
D010837	Vitamin K 1	CYP4F2 gene SNP affects the abundance of Vitamin K 1	25747538
D010837	Vitamin K 1	CYP4F2 protein results in increased oxidation of Vitamin K 1	19297519
D014859	Warfarin	CYP4F2 gene affects the susceptibility to Warfarin	19207028
D014859	Warfarin	CYP4F2 gene mutant form affects the susceptibility to Warfarin	20553802
D014859	Warfarin	CYP4F2 gene polymorphism affects the susceptibility to Warfarin	18250228\|1927026
D014859	Warfarin	[CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin	21084764
D014859	Warfarin	CYP4F2 gene SNP affects the susceptibility to Warfarin	20442691\|2083365
D014859	Warfarin	CYP4F2 polymorphism affects the susceptibility to Warfarin	20653676\|2306174
D014859	Warfarin	CYP4F2 protein polymorphism affects the susceptibility to Warfarin	23215885
D014859	Warfarin	CYP4F2 protein results in increased susceptibility to Warfarin	18250228
D014859	Warfarin	CYP4F2 SNP affects the susceptibility to Warfarin	28079798

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004497	monooxygenase activity	-	TAS	-
GO:0005506	iron ion binding	-	IEA	-
GO:0005515	protein binding	-	IPI	17474147 25910212
GO:0008392	arachidonic acid epoxygenase activity	-	IDA	9618440 20861217
GO:0016709	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	-	IDA	19297519 24138531
GO:0018685	alkane 1-monooxygenase activity	-	IDA	18433732
GO:0020037	heme binding	-	IEA	-
GO:0050051	leukotriene-B4 20-monooxygenase activity	-	IDA	8026587 9799565
GO:0050051	leukotriene-B4 20-monooxygenase activity	-	TAS	-
GO:0052869	arachidonic acid omega-hydroxylase activity	-	IDA	9618440 10660572
GO:0052871	alpha-tocopherol omega-hydroxylase activity	-	IDA	20861217
GO:0052872	tocotrienol omega-hydroxylase activity	-	IDA	20861217
GO:0097258	20-hydroxy-leukotriene B4 omega oxidase activity	-	TAS	-
GO:0097259	20-aldehyde-leukotriene B4 20-monooxygenase activity	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000038	very long-chain fatty acid metabolic process	-	IDA	18433732
GO:0001676	long-chain fatty acid metabolic process	-	IDA	18433732
GO:0003091	renal water homeostasis	-	IEP	10660572
GO:0003095	pressure natriuresis	-	IEP	10660572
GO:0006690	icosanoid metabolic process	-	TAS	-
GO:0006691	leukotriene metabolic process	-	TAS	-
GO:0007596	blood coagulation	-	TAS	19297519 24138531
GO:0008217	regulation of blood pressure	-	IMP	18391101
GO:0017144	drug metabolic process	-	IMP	21084764 21127708
GO:0019369	arachidonic acid metabolic process	-	IDA	10660572
GO:0019373	epoxygenase P450 pathway	-	IDA	9618440 20861217
GO:0032304	negative regulation of icosanoid secretion	-	IMP	18391101
GO:0032305	positive regulation of icosanoid secretion	-	IMP	17341693
GO:0036101	leukotriene B4 catabolic process	-	IDA	8026587 9799565 10492403
GO:0042360	vitamin E metabolic process	-	IDA	20861217
GO:0042361	menaquinone catabolic process	-	IDA	24138531
GO:0042376	phylloquinone catabolic process	-	IDA	24138531
GO:0042376	phylloquinone catabolic process	-	IEA	-
GO:0042377	vitamin K catabolic process	-	IDA	19297519 24138531
GO:0055078	sodium ion homeostasis	-	IEP	10660572
GO:0055114	oxidation-reduction process	-	IDA	9618440 9799565 20861217
GO:0097267	omega-hydroxylase P450 pathway	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	IDA	10660572
GO:0005789	endoplasmic reticulum membrane	-	TAS	20861217
GO:0016324	apical plasma membrane	-	IDA	10660572
GO:0031090	organelle membrane	-	IEA	-
GO:0043231	intracellular membrane-bounded organelle	-	IDA	9618440 9799565 10660572 20861217 24138531

KEGG ID	KEGG Term
hsa00590	Arachidonic acid metabolism
hsa01100	Metabolic pathways

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-211859	Biological oxidations	TAS
R-HSA-211897	Cytochrome P450 - arranged by substrate type	TAS
R-HSA-211935	Fatty acids	TAS
R-HSA-211945	Phase I - Functionalization of compounds	TAS
R-HSA-211958	Miscellaneous substrates	TAS
R-HSA-211979	Eicosanoids	TAS
R-HSA-2142691	Synthesis of Leukotrienes (LT) and Eoxins (EX)	TAS
R-HSA-2142753	Arachidonic acid metabolism	TAS
R-HSA-2142816	Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)	TAS
R-HSA-556833	Metabolism of lipids	TAS
R-HSA-8978868	Fatty acid metabolism	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
21110013	Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. (2011 Apr)	Geisen C	Eur J Clin Pharmacol
29500141	Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population. (2018 Mar)	Peng C	Clin Ther
28049362	Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. (2018 Mar)	Gaikwad T	Clin Appl Thromb Hemost
26739746	A multi-factorial analysis of response to warfarin in a UK prospective cohort. (2016 Jan 6)	Bourgeois S	Genome Med
23846787	Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcinoma. (2013 Dec)	Gandhi AV	Ann Surg Oncol
24911077	CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. (2014 Apr)	Nahar R	Pharmacol Rep
21228733	Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. (2011 Mar)	Shahin MH	Pharmacogenet Genomics
22629463	Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. (2012)	Rathore SS	PLoS One
25712182	Effect of clinical factors and gene polymorphism of CYP2C192, 17 and CYP4F2*3 on early stent thrombosis. (2015)	Kupstyte N	Pharmacogenomics
23061746	Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. (2013 Mar)	Ozer M	Basic Clin Pharmacol Toxicol